Additional Xiaflex® Treatment in Patients With Peyronie's Disease Recurrence, Worsening, or Incomplete Response

NCT03767452 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Peyronie's Disease

Interventions

DRUG: Xiaflex® 0.58 mg

Sponsor

Manhattan Medical Research Practice, PLLC

Collaborators

[object Object]